(Q43032263)

12 November 2017

title

Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. (English)

1 reference

12 November 2017

6

Zilton Andrade

1 reference

12 November 2017

Raymundo Paraná

1

1 reference

12 November 2017

Maria Isabel Schinoni

2

1 reference

12 November 2017

Luiz A R de Freitas

3

1 reference

12 November 2017

Liana Codes

4

1 reference

12 November 2017

Marla Cruz

5

1 reference

12 November 2017

Christian Trepo

7

1 reference

12 November 2017

publication date

1 November 2006

1 reference

12 November 2017

1 reference

12 November 2017

volume

26

1 reference

12 November 2017

issue

9

1 reference

12 November 2017

page(s)

1148-1154

1 reference

Global epidemiology and burden of hepatitis C.

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Extrahepatic manifestations of HCV infection: facts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Approach to the patient with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Pegylated interferons for the treatment of chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Adverse effects and other safety aspects of the hepatitis C antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Side effects of therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Management of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Hashimoto encephalopathy with pegylated interferon alfa-2b and ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Autoantibodies to Golgi proteins in hepatocellular carcinoma: case report and literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Hepatitis B virus immunopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

Immunology of viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01345.X

10.1111/J.1478-3231.2006.01345.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference